Johnson & Johnson Innovation, has announced 12 new alliances with life science companies and research institutions around the globe to explore early-stage innovation in a range of therapeutic areas and across pharmaceuticals, medical device and diagnostics and consumer healthcare.
“The future of healthcare will be defined by companies, academic institutions and governments that collaborate to leverage existing strengths, while at the same time think outside current paradigms and experiment with new ways of innovating,” said Paul Stoffels, chief scientific officer, Johnson & Johnson and worldwide chairman, pharmaceuticals.
“By being where these new frontiers in science and technology are being forged, our goal is to translate these insights into promising treatments for the future.”
Launched more than a year ago, the Johnson & Johnson Innovation centres are working globally with life science researchers and entrepreneurs to identify exciting early-stage technologies and translate them into solutions for patients.
The early-stage collaborations announced represent recent research and development alliances facilitated by the Boston, California and London innovation centres and include technologies like 3D printing for orthopaedic trauma, sedation monitoring, cardiac remodeling and probiotics for skin infections.
“The broad variety of the collaborations we are announcing, and the unique ways in which we are working with our collaborators, illustrates our strong commitment to being flexible and creative in our deal making in order to maximize the potential of each individual technology,” added Stoffels. “Our goal is to enrich the life science ecosystem on a global scale by redefining the R&D paradigm.”